Quick Facts: Amikacin

• May be utilized as a component of treatment for serious infections caused by susceptible bacteria.
• May be administered for certain infections of the respiratory tract, abdomen, bone and joint, and central nervous system.
• Used in a limited population of adults who have few or no alternative options for the management of Mycobacterium avium complex (MAC) lung disease.

---

Amikacin is an antibiotic that may be incorporated into regimens for treating a range of serious infections due to susceptible Gram-negative bacteria. This medication may be employed for short-term management of conditions such as sepsis and other critical infections of the blood. It may also provide therapeutic benefit in certain severe infections that affect the respiratory tract, including the lungs, as well as infections in the bones and joints, and the abdomen, such as peritonitis.

Additionally, an inhaled form of Amikacin is available for the management of Mycobacterium avium complex (MAC) lung disease in a specific adult patient population. This particular use is reserved for patients who have limited or no alternative treatment options and whose disease has not responded to other multidrug regimens. When administered intravenously or intramuscularly, it may be used in combination with other agents to address severe bacterial infections, including those that show resistance to other antibiotics.

Regulatory References

1. NIH MedlinePlus guidance

Who can and cannot use Амикацин

Official regulatory documents strictly define the population eligibility for Amikacin, primarily focusing on hypersensitivity, renal function, and life stage risks.

---

Eligibility Scope

Classification	Eligible Populations and Restrictions
Populations Allowed	Adults, children, and older infants are permitted for short-term use against susceptible bacteria. Neonates and premature infants may use the medicine with caution due to renal immaturity.
Absolute Contraindications	Contraindicated in individuals with a known hypersensitivity or allergy to Amikacin or any other aminoglycoside antibiotic [1.1].
Pregnancy and Lactation	Contraindicated during pregnancy due to the officially documented risk of total, irreversible, bilateral congenital deafness in the fetus [1.1]. During lactation, a regulatory decision is required to discontinue either breastfeeding or the drug [2.2].

---

Condition-Specific Eligibility Rules

• Renal Impairment: Patients with impaired renal function require cautious use, close monitoring, and mandatory dose adjustment [1.1]. Individuals with pre-existing renal damage have a greater risk of toxicity [2.1].
• Neuromuscular Conditions: Patients with disorders like Myasthenia Gravis or Parkinsonism require caution, as the drug may aggravate muscle weakness [1.5].
• Advanced Age: Older adults may have an increased risk of toxicity and must have their renal function closely monitored [1.5].
• Duration: Safety for treatment periods longer than 14 days has not been established [2.1].

---

Regulatory Summary

Official eligibility statements establish absolute non-eligibility based on prior drug sensitivity and pregnancy status. Use in all other populations is conditional on monitoring organ function and pre-existing comorbidities, requiring that populations such as those with impaired renal function, neuromuscular disorders, or neonates be treated with strict caution as defined by labeling [1.1], [1.2].

Interactions with other medicines and products

Amikacin's interaction profile is characterized by pharmacodynamic synergy, resulting in enhanced organ toxicity and neuromuscular effects, alongside specific constraints on physical administration.

Interaction Domain	Mechanism and Interacting Agents (Official Regulatory Information)
Additive Toxicity Risk	Co-administration with other nephrotoxic products (cisplatin, vancomycin, polymyxin B) or ototoxic products (loop diuretics like furosemide or ethacrynic acid) may result in the additive enhancement of kidney or eighth cranial nerve toxicity. Concurrent or sequential use with these agents is generally restricted or discouraged.
Neuromuscular Potentiation	Amikacin may potentiate the effects of neuromuscular blocking agents and anesthetics, leading to enhanced skeletal muscle relaxation and possible apnea. This risk is heightened in patients with neuromuscular disorders like Myasthenia Gravis or Parkinson's disease.
Administration Incompatibility	Amikacin and beta-lactam antibiotics must not be physically mixed in the same intravenous solution. This is a mandatory timing rule to prevent the in vitro chemical inactivation of Amikacin, which would reduce drug exposure and activity.
Exposure Modification	Co-administration of Indomethacin in neonatal patients may cause an increase in Amikacin plasma concentrations, which is a population-specific note related to heightened toxicity risk.

The regulatory documents establish strict boundaries for use with specific classes of medicines to manage the risk of additive toxicity. The interaction profile mandates the physical separation of administration from certain antibiotics to prevent chemical degradation and formally cautions against potentiated effects with neuromuscular blocking agents. These official statements define the core constraints for co-administration.

Targeting the 30S Ribosomal Subunit for Irreversible Binding

Amikacin's core mechanism involves irreversible binding to the bacterial 30S ribosomal subunit, the key molecular target that controls protein assembly. This binding immediately inhibits the microbe's translation process, which is necessary to initiate a cascade of cellular damage.

Mechanistic Cascade: Misreading, Membrane Damage, and Cell Death

The binding causes the ribosome to misread its genetic code, producing vast amounts of defective, non-functional proteins. The incorporation of these faulty proteins into the bacterial membrane creates structural lesions, which rapidly amplify the drug's uptake and lead directly to bactericidal action (microbial killing).

Uptake Dependence and Enzymatic Limitations

The bactericidal potential of this mechanism depends on active, energy-dependent uptake into the bacterial cell, which is diminished in environments lacking oxygen or high acidity. Furthermore, the mechanism can be overridden if bacteria produce specific enzymes, such as AAC(6')-Ib, which inactivate the Amikacin molecule before it can reach its ribosomal target.

Administration Route and Delivery

Amikacin's administration involves specific methods, doses, and durations of use. The drug is primarily administered systemically as an Intravenous (IV) infusion or Intramuscular (IM) injection. A specialized liposomal form is used for Oral Inhalation via a designated nebulizer system, intended for localized treatment in specific patient populations.

---

Official Dosing Regimens

For patients with normal renal function, the standard parenteral dose is generally 15 mg/kg per day, based on body weight, which may be given as a single daily dose or divided into 7.5 mg/kg every 12 hours. The maximum total daily dose for the injectable solution should not exceed 1.5 grams. The usual duration for this systemic treatment is limited to 7 to 10 days.

---

Preparation and Special Conditions

Intravenous solutions must be diluted before use and administered slowly over a period of 30 to 60 minutes in adults. Dosage for the systemic form requires therapeutic drug monitoring, involving the intermittent measurement of peak and trough serum concentrations to guide dosing.

Dosage adjustments are specifically mandated for patients with impaired renal function, calculated based on measures such as creatinine clearance. Specific dose adjustments are also required for obese patients, where the calculation utilizes ideal body weight with an adjustment for excess weight.

For the inhalation form, pre-treatment with a short-acting bronchodilator is required for patients with hyperreactive airways. If a daily dose of the inhalation suspension is missed, the patient should not double the dose, but resume the regimen with the next scheduled dose.

Research Evidence / Overview of Studies for Amikacin

---

Evidence for Use in Severe Bacterial Infections

Research has examined Amikacin was studied for conditions associated with acute or disruptive episodes, such as severe Gram-negative bacterial infections. These studies have included short-term Clinical Trials and Retrospective Analyses. Researchers monitored several key outcomes describing episodic or acute changes, including monitoring of microbiological status to assess pathogen activity and outcomes related to microbiological eradication and patient status during the study period. Studies also focused on understanding how the drug moves through the body using specialized Pharmacokinetic (PK) research.

Studies monitored various endpoints reflecting physiological strain or stress and systemic or functional imbalance in groups of patients who had infections in the respiratory tract, abdomen, bones, joints, or bloodstream (sepsis). These trials generally focused on research exploring short-term symptom changes over the course of treatment. The follow-up durations were limited in many studies, meaning there is limited information for long-term outcomes once the course is complete. Research describes wide variability in drug levels in critically ill patients, suggesting that achieving specific drug concentrations can be a complex task in this population.

Evidence for Use Against Multi-Drug Resistant Bacteria

Studies was evaluated in adults with severe infections focusing on outcomes related to systemic or functional imbalance where the bacteria were documented as resistant. Comparative studies have explored the outcomes related to Amikacin's use when studied alongside or against other therapeutic approaches. Studies report how symptoms evolved in the observed populations related to microbiological status across resistant infection types.

Evidence for Use in Refractory MAC Lung Disease

Amikacin was studied for patients with Mycobacterium avium complex (MAC) lung disease. A specific inhaled formulation was evaluated in a narrow group of adult patients whose disease had not responded to other extensive treatment regimens. The research examined outcomes related to systemic or functional imbalance by primarily tracking whether the bacteria could still be found in the sputum (culture conversion) over a long-term observation period. Researchers noted that achieving target drug levels in the bloodstream can be variable, and this was monitored across patients receiving the inhaled drug.

What Remains Uncertain About Amikacin Research

Evidence highlights what is known — and what is still uncertain about the research base for Amikacin. A primary gap is that long-term effects are not fully established across most indications, as follow-up durations were limited for short-course injectable uses. Additionally, the sample sizes were modest in some specific trials, and research describes that drug concentrations can be variable, leading to uncertainty in specific patient groups.

Key Studies & References Amikacin: Drug Information (MedlinePlus)

Common questions about Амикацин (FAQ)

Q: Can Амикацин cause permanent hearing loss, and how often does this happen?

Regulatory documents indicate that ototoxicity, which includes hearing loss, is a serious risk associated with Amikacin use and may be permanent. The official product information confirms the potential for this irreversible side effect. Specific rates describing how often this occurs are not typically provided in the patient-facing materials.

Q: Is it possible for side effects to occur even after treatment with Амикацин has stopped?

Official product warnings indicate that ototoxicity, which affects hearing, may occur during therapy or sometimes even after Amikacin treatment has been stopped. This possibility is noted as a specific safety consideration mentioned in regulatory documents.

Q: Can Амикацин cause diarrhea, and when should I be concerned about it?

Official documents list Clostridium difficile-associated diarrhea (CDAD) as a serious adverse reaction reported with the use of Amikacin. This specific type of persistent diarrhea is listed in official safety information as a clinically significant event that requires medical evaluation.

Q: Does taking other antibiotics at the same time affect how Амикацин works?

According to official product information, the drug is subject to physical incompatibility rules during the administration process with certain other antibiotics, such as beta-lactams. Additionally, co-administration with other medicines known to be nephrotoxic (toxic to the kidneys) is generally restricted due to the potential for enhanced side effects.

Q: What happens if a patient misses one scheduled dose of Амикацин?

Instructions for a single missed dose of the systemic (IV or IM) form are typically not included in general patient information. Management of any missed dose is determined by the healthcare provider overseeing the patient’s clinical protocol.

Q: Does Амикацин treat infections caused by viruses like the flu or common cold?

Regulatory documents explicitly define Amikacin's intended use as treating serious infections caused by susceptible bacteria. It is not approved or intended for the treatment of viral infections, such as the common cold or the flu.

Q: Is it common to experience pain or redness at the injection site?

Official adverse reaction lists include local site reactions as reported occurrences. These can include pain at the injection site following an intramuscular dose, or irritation and swelling of a vein (phlebitis) following an intravenous infusion.

Q: What is the connection between certain genetic conditions and the risk of hearing loss from Амикацин?

Official warnings state that individuals with certain mitochondrial mutations may have an increased, permanent risk of developing drug-induced hearing loss when using Amikacin. This is a specific safety consideration noted in official documents.

Q: Can I use common pain relievers like Ibuprofen or Naproxen while on Амикацин?

Regulatory documents caution against co-administration with other medications known to be nephrotoxic (kidney-toxic). Since many common pain relievers, such as non-steroidal anti-inflammatory drugs (NSAIDs), are described as potentially having this effect, the management of this risk is determined by a healthcare provider.

Q: Is it necessary to finish the entire prescribed course of Амикацин, even if symptoms improve quickly?

Official patient information indicates the importance of completing the full prescribed duration for antibiotics like Amikacin. This practice is cited as important to help ensure the infection is completely eliminated.

Q: Does dehydration affect the safety of Амикацин use?

Official prescribing information mandates close monitoring and possible dose adjustments based on renal function (how well the kidneys are working). Therefore, any condition, such as dehydration, that affects the health or function of the kidneys could potentially impact how the drug is cleared from the body and influence its safety profile.

Q: Are there specific dietary restrictions while receiving Амикацин?

According to the official regulatory documents, there are generally no specific restrictions regarding food or diet required while a patient is receiving the injectable form of Amikacin.

How to Store and Dispose of Amikacin

Official regulatory guidelines strictly define the storage and disposal requirements for Amikacin (Amikacin Sulfate) injection.

---

Storage Requirements

Amikacin Sulfate Injection must be stored at a controlled room temperature, specifically 20 C to 25 C (68 F to 77 F), and must be protected from freezing. The medication must be kept in its original container at all times. Before use, the solution must be visually inspected, and it must not be used if it appears discolored or contains any precipitate.

---

Disposal and Safety

To prevent accidental exposure, Amikacin must be kept out of the sight and reach of children. Any unused product or expired waste material must be properly discarded. Disposal must be conducted in accordance with local requirements established for pharmaceutical waste.